ATS 2019 Virtual Final Program

10:35 Should Patients with Mildly Increased Pulmonary Artery Pressure Be Diagnosed with and Treated for Pulmonary Hypertension? Yes E. Brittain, MD, Nashville, TN 10:50 Should Patients with Mildly Increased Pulmonary Artery Pressure Be Diagnosed with and Treated for Pulmonary Hypertension? No G. Kovacs, MD, Graz, Austria 11:05 Should Patients with Mildly Increased Pulmonary Artery Pressure Be Diagnosed With and Treated for Pulmonary Hypertension? Open Discussion M.R. Lammi, MD, MSCR, New Orleans, LA This session and the International Conference are supported by an educational grant from Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A9 NOVEL BIOMARKERS FOR THE DIAGNOSIS, PHENOTYPING, AND MANAGEMENT OF PEDIATRIC LUNG DISEASES Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Dallas Ballroom A-C (Level 3) Target Audience This session will appeal to primary care providers, nurses, trainees, and subspecialists who care for children with lung diseases, as well as scientists conducting pediatric pulmonary research Objectives At the conclusion of this session, the participant will be able to: • learn new findings on novel biomarkers of pediatric pulmonary diseases such as viral acute respiratory infections, pulmonary vascular diseases, primary ciliary dyskinesia, asthma, and rare lung diseases; • review the clinical implications of these findings and how they could impact personalized pediatric pulmonary medicine; • explore future directions for research aimed at biomarker discovery for pediatric pulmonary diseases. Our understanding of the pathophysiology of pediatric pulmonary diseases has advanced exponentially over the past several years. This, together with marked improvements in laboratory techniques, omics approaches, and data analysis methods, has led to the discovery of novel measurements that can aid in the diagnosis, phenotyping, and management of childhood respiratory illnesses. In this session, we will discuss the latest developments and clinical implications of biomarkers of pediatric pulmonary conditions such as viral acute respiratory infections, pulmonary vascular disease, primary ciliary dyskinesia, asthma, and rare lung diseases, and explore future directions in the field. Chairing: C. Rosas-Salazar, MD, MPH, Nashville, TN E. Forno, MD, MPH, ATSF, Pittsburgh, PA 9:15 Introduction C. Rosas-Salazar, MD, MPH, Nashville, TN 9:20 Predicting Short- and Long-Term Outcomes of Viral Acute Respiratory Infections in Infancy C. Rosas-Salazar, MD, MPH, Nashville, TN 9:43 Biomarker Discovery for Pediatric Pulmonary Vascular Diseases S.H. Abman, MD, Aurora, CO 10:06 Improving the Diagnosis of Primary Ciliary Dyskinesia S.D. Davis, MD, ATSF, Chapel Hill, NC 10:29 Epigenetics and Transcriptomics in the Prediction and Phenotyping of Childhood Asthma E. Forno, MD, MPH, ATSF, Pittsburgh, PA 10:52 Emerging Biomarkers of Pediatric Rare Lung Diseases L.R. Young, MD, ATSF, Nashville, TN This session and the International Conference are supported by educational grants from Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals . All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 A10 TREATING ASTHMA IN PATIENTS WITH OBESITY: THE NEED FOR A NEW APPROACH Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Sleep and Respiratory Neurobiology 9:15 a.m. - 11:15 a.m. KBHCCD Room D221/D225/D226 (Level 2) Target Audience Clinicians taking care of obese patients, translational investigators working in basic science, epidemiology and behavioral science Objectives At the conclusion of this session, the participant will be able to: • understand the effects of obesity on respiratory physiology and immune function; • develop a rationale approach to treating obese patients with asthma; • explain how comorbidities complicate treatment of asthma in obesity. Obesity is a major risk factor for asthma, and nearly 60% of patients with severe asthma are obese. Obese patients do not respond as well to standard therapies; this represents a major challenge to clinicians and a public health crisis. This session will discuss the pathophysiology of the different phenotypes of obese asthma, and how this affects treatment responses. The role of medications, life-style interventions,and ATS 2019 • Dallas, TX SUNDAY • MAY 19 29 SUNDAY MORNING